MedTrace Logo

Clinical Intervention Strategy for High-risk Group of Hepatitis B Related Hepatocellular Carcinoma

NCT05256459 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2022-05-09

No results posted yet for this study

Summary

This study aims to explore whether there is difference in the incidence rate and incidence rate of HCC in patients with chronic hepatitis B who are screened for high risk of liver cancer. Whether the timely intervention can be used to reduce the incidence of HCC for the early screening and early warning patients can provide evidence-based medical evidence for the selection or adjustment of anti HBV drugs in high-risk patients with liver cancer. To provide evidence for whether patients with liver nodules at high risk of liver cancer need to deal with liver nodules in advance.

Conditions

  • Time

Interventions

OTHER

Long term follow-up

No extra intervention.

Sponsors & Collaborators

  • Chongqing Three Gorges Central Hospital

    collaborator OTHER

  • The Affiliated Hospital Of Southwest Medical University

    collaborator OTHER

  • Chongqing Public Health Medical Center

    collaborator OTHER

  • Zhang Dazhi,MD

    lead OTHER

Principal Investigators

  • Dazhi Zhang, Doctor · The Second Affiliated Hospital of Chongqing Medical University

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-10
Primary Completion
2024-12-15
Completion
2024-12-15

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05256459 on ClinicalTrials.gov